Balancing Capitalism and Innovation in Cancer Medicine

• Capitalism and profit incentives are valuable for driving innovation in cancer medicine.
• The current system fails to distinguish between real innovation and pseudo-innovation in drug development.
• Truly transformational drugs should receive large returns on investment.
• The technical complexity of the system makes it difficult for average people to discern between effective drugs and those with strong marketing.
• Reimbursing both types of drugs similarly is problematic.